View More Recent Stories
-
Cantor Fitzgerald Reiterates Overweight Rating on Vera Therapeutics (VERA)
-
Vera Therapeutics Inc. (VERA) Weakness Tied to Rival Drug, Analyst Says
-
JPM just added these stocks to its Analyst Focus List - giving one 148% upside
-
Vera Therapeutics Inc. (VERA) Announces Proposed $300M Share Offering
-
TD Cowen Reiterates Buy Rating on Vera Therapeutics (VERA)
-
Evercore ISI Reiterates Outperform Rating on Vera Therapeutics (VERA)
-
Vera Therapeutics (VERA) Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases
-
Vera Therapeutics Inc. (VERA) Announces Late-Breaking Oral Presentation of ORIGIN Phase 2b Long-term Results
-
JPMorgan refreshed its U.S. Analyst Focus List, adding these six stocks
-
JPM just refreshed its US Analyst Focus List, adding these 5 stocks
-
JPMorgan refreshed its U.S. Analyst Focus List and added these four names
-
Vera Therapeutics (VERA) PT Raised to $72 at JPMorgan, Added to AFL
-
Vera Therapeutics, Inc. (VERA) Misses Q2 EPS by 6c
-
Vera Therapeutics (VERA) Announces Appointment of Industry Veteran David L. Johnson as Chief Operating Officer
-
Vera Therapeutics (VERA) Appoints Christy J. Oliger to Board of Directors
